The highs of cannabis testing

Globally there is a strong indication of efforts now implemented in the commercialisation of cannabis, underscored by a recent SABC news article entitled Cannabis craze weeds out junior mining field.1 According to the article, the world’s top three listed cannabis companies – Canopy Growth, Tilray and Aurora Cannabis – have a combined market value of around USD30 billion. This year, consumers are expected to spend over USD7 billion on cannabis products in Canada alone, reports Deloitte. The recent Cape Town Cannabis Expo drew 16 500 visitors on its first day.2

Clinical targets

Over the last 25 years, the endocannabinoid system (ECS) has emerged as an important neuromodulatory system. ECS is comprised of cannabinoid receptors, endogenous cannabinoids (endocannabinoids) and the enzymes responsible for the synthesis and degradation of these. 3 The endocannabinoid anandamide has been linked to the so-called ‘runners high’, experienced by some endurance athletes. 4

The effects of certain plant-based cannabinoids, THC in particular needs no introduction. Another is cannabidiol (CBD), which on 25 June 2018 became the first CBD based product available on the US Market, as Epidiolex. 5 Supplementation with CBD is on the increase and presentation of a suitable product or supplement is likely to be met with very good returns.Yet the poor oral bioavailability (six to19 percent) 6,7 , largely attributed to high lipophilicity, presents a challenge. Recent findings 8 that Cmax is increased during fed states and in lipid formulations are clues to be considered when applying new formulation strategies with the end goal of improved bioavailability and product differentiation.

The instrument lab (left) and prep lab (right) at V&M Analytical Toxicology Laboratory Services